The global immunohistochemistry market was valued at USD 2.01 billion in 2023. The size of the global IHC market is forecasted to value USD 3.82 billion by 2032 from USD 2.16 billion in 2024, growing at a CAGR of 7.4% from 2024 to 2032.
Immunohistochemistry is a staining procedure done on fresh or stored cancer tissue removed during the biopsy. IHC detects if the cancer cells have hormone receptors on their surface. IHC is majorly used for the diagnosis of cancers, especially tumor antibodies.
The growing cancer prevalence and the increasing geriatric population drive the immunohistochemistry market growth. Other factors, such as increasing healthcare expenditure and improving healthcare infrastructure, thus leading to more hospitals and diagnostic laboratories daily, are anticipated to result in the growth of the IHC market. In addition, the growing adoption of technologically advanced immunohistochemistry solutions and growing drug discovery & development activities are boosting the market’s growth rate.
Rising approvals of products and the introduction of technologically advanced immunohistochemistry solutions for disease diagnosis further favor the global immunohistochemistry market growth. In addition, the involvement of major players in developing IHC solutions by collaborating with pharmaceutical drug manufacturers to develop and provide IHC companion diagnostic solutions for their immunotherapies offers lucrative opportunities for the market participants operating in the IHC market. Furthermore, rising awareness levels regarding chronic diseases among people are anticipated to promote the demand for immunohistochemistry solutions, which is eventually expected to result in the growth of the IHC market.
Furthermore, the new immunohistochemistry applications in new fields are anticipated to favor the IHC market growth. For instance, a research paper by G.F. Ingrassia, Department of Medical, Surgical and Advanced Technologies, University of Catania, Italy, in collaboration with multiple other institutes published in august of 2022, emphasizes the use of IHC in determining the accurate time of death for a body. The time of death is an essential part of the investigation for the FBI and several investigational organizations; thus, this discovery benefits them. Furthermore, the applications of IHC in detecting several neurodegenerative disorders due to multiple causes, such as cannabidiol use and smoking cigarettes, are expected to support the market’s growth rate.
However, the lack of specificities associated with IHC techniques and its high setup cost are significant restraints limiting the growth of the global immunohistochemistry market. The lack of specificity of IHC techniques for diagnosing some chronic diseases is a significant challenge for the Immunohistochemistry market. In addition, the considerable burden and high setup cost of IHC equipment in hospitals and diagnostic laboratories among emerging economies are the other factors limiting the growth of the target market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Various Analyses Covered |
Global, Regional & Country Level Analysis; Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities |
Segments Analysed |
By Application, Technology, Patient Care Setting & Region |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Market Leaders Profiled |
F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc. |
Based on the product, the antibodies segment is predicted to lead the global immunohistochemistry market during the forecast period. The mandatory use of antibodies in carrying out the immunohistochemistry diagnosis of diseases such as cancer, infectious diseases, and other diseases propels segmental growth. In addition, the growing usage of research antibodies for drug discovery is another major factor contributing to the growth of the antibodies segment.
The IHC kits segment is also expected to grow significantly during the forecast period due to the convenience of using kits and the ease it provides in research and development activities for academic and biotechnological procedures. In addition, the sorted kits, which can be used without the hassle of measuring accurate antibody stains for tissues, save a lot of time and help avoid human errors in the procedure, driving the demand for the segment. Furthermore, many key players are now providing kits and assays as the R&D in the field of immunohistochemistry rises leading to segment growth.
Based on the application, the diagnostic segment accounted for the largest share of the Immunohistochemistry market in 2023. The growing incidence & prevalence of cancer majorly drive the segment's growth. Also, the burden of infectious diseases and the favorable reimbursement scenario for IHC tests is other factors growing the segment's share in the market.
However, due to the multiple immunohistochemistry applications in drug testing, the segment is expected to grow notably during the forecast period. Immunohistochemical staining and histomorphometry quantification are widely used in procedures like drug discovery, drug efficacy, drug repositioning, biomarker expressions, etc. Therefore, they are extensively used by pharmaceutical and biotechnology companies resulting in growth for the segment.
Based on the end-users, the hospitals & diagnostics laboratories segment captured the largest share of the global IHC market in 2023 and is forecasted to showcase the lead in the global market throughout the forecast period owing to the growing adoption of technological advancements such as automated sample preparation and digital pathology, which have added considerable value. Also, the growing demand for disease diagnosis due to the rise in the incidence of chronic diseases is the other factor that has contributed significantly to the segment’s growth in the recent past.
The research and development segment of the market is also expected to have grown during the forecast period due to the efficiency of the IHC staining procedures and its advantages over traditional special enzyme staining techniques. In addition, IHC has become an essential tool for detecting neurodegenerative disorders via abnormal proteins in research applications for human and animal cells, supporting the segment's growth.
Geographically, the IHC market in North America led the worldwide market in 2023, owing to biotech and commercialization advancements. The dominance of the North American region can be credited to the growing adoption of these immunohistochemistry instruments in laboratories & diagnostic centers. In addition, favorable reimbursement policies in countries such as the US and Canada boost the penetration of automated devices, promoting the growth of the IHC market in the North American region. Furthermore, an increase in the number of people with cancer from North American countries is anticipated to demand these immunohistochemistry techniques. For instance, according to the American Cancer Society, in 2019, it was reported that 1,762,450 new cancer cases were diagnosed, and more than 606,880 cancer deaths in the United States.
On the other hand, the IHC market in the Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period. The rapid growth of the immunohistochemistry market in the Asia-Pacific region is attributed to the economic development in countries such as China, India, South Korea, and Singapore. Besides, the rapid growth of the aging population and the high prevalence of chronic diseases are the other factors fuelling the Asia-Pacific Immunohistochemistry Market development. Moreover, WHO estimates that the annual events of CVDs are predicted to rise by 50% in China between 2010 and 2030.
The IHC market in Europe is expected to grow at a healthy CAGR in the coming years following the Asia Pacific. Constant economic growth and rising disposable income in urban areas are mainly propelling the market demand in this region.
The IHC market in Latin America is also growing due to the increasing incidences of cancer, stabilization of the economy over the past years, growing expenditure on healthcare, developing infrastructure, and rising disposable income.
The IHC Market in the Middle East & Africa is estimated to register a growth rate of 7.3% during the forecast period.
A few of the notable companies leading the global immunohistochemistry market profiled in this report are F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc.
By Product
By Application
By End User
By Region
Frequently Asked Questions
The global immunohistochemistry market size was valued at USD 2.01 billion in 2023.
The growing patient pool suffering from chronic diseases and increasing adoption of technological developments are propelling market growth.
The North American region had the largest share of the global market in 2023.
F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc. are some of the noteworthy players in the immunohistochemistry market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region